<p><strong> </strong><strong>Clinicians should provide an individualized risk estimate of post-treatment prostate cancer recurrence to patients with prostate cancer.<em> (Clinical Principle)</em></strong></p>
Discussion
Discussion
<p>Post-treatment cancer recurrence risk is dependent on a number of clinicopathologic factors, including most notably tumor grade and stage, as well as pretreatment PSA and, for patients undergoing radical prostatectomy, surgical margin status.<sup>118</sup> Multiple predictive models and nomograms have been developed to estimate the risks of biochemical recurrence, metastases, and death from prostate cancer.<sup>12, 13, 119-121</sup> These tools may be used to support discussions with patients regarding their personalized risk. In addition, competing risks of mortality from patient age and comorbidity status should be considered. Discussion of risk is a particularly important aspect of patient counseling and SDM.</p>